Skip to main content
The DEPICT Act

The DEPICT Act

Are you prepared for the DEPICT Act?

The industry is making significant headway in delivering diversity in clinical trials, and the time to do more is now. 

On February 3, 2022, Rep. Eshoo (D-CA), Chairwoman of the Energy and Commerce Health Subcommittee, Rep. Fitzpatrick (R-PA), and Rep. Kelly (D-IL) introduced the Diverse and Equitable Participation in Clinical Trials (DEPICT) Act, which is new US legislation aimed at boosting diversity in clinical trials. The DEPICT Act requires Investigational New Drug and Investigational Device Exemption applicants to:

  • Report clinical trial enrollment targets by demographic subgroup
  • Provide a Diversity Action Plan detailing the actions the sponsor will take
  • Provide the FDA with the authority to mandate post-market studies when sponsors fail to meet diversity enrollment targets and do not provide a sufficient justification.

At Science 37®, diversity is at our core. Our Diversity in Clinical Trials unit is already working with sponsors to develop and implement action plans to reach diversity enrollment targets.

To learn more about the DEPICT act and about how we can help your clinical trials be more diverse, please fill out the form. A member of our team will be in touch.